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The existence of a stem cell niche, or physiological microenvironment, consisting of specialized cells
that directly and indirectly participate in stem cell regulation has been verified for mammalian adult
stem cells in the intestinal, neural, epidermal, and hematopoietic systems. In light of these findings, it
has been proposed that a ‘‘cancer stem cell niche’’ also exists and that interactions with this tumor
niche may specify a self-renewing population of tumor cells. We discuss emerging data that support
the idea of a veritable cancer stem cell niche and propose several models for the relationship
between cancer cells and their niches.The Concept of the Normal Stem Cell Niche
In normal adult tissues, stem cells depend on the integra-
tion of both cell-intrinsic and cell-extrinsic factors for
proper, homeostatic tissuemaintenance. The two cardinal
characteristics of a stem cell are the capacity both to self-
renew, or make more stem cells, and to differentiate, or
give rise to the full repertoire of specialized cells that com-
prise the tissue in question. Achieving a delicate balance
between these two opposing processes is critical in the
adult organism for maintaining proper tissue homeostasis
and for repair and regeneration of tissues after injury.
Excessive differentiation at the expense of self-renewal,
for instance, can deplete the stem cell pool, whereas
excessive self-renewal could lead to aberrant expansion
and even tumorigenesis. In 1978, Schofield proposed
the existence of a niche, or specialized location, for hema-
topoietic stem cells (HSCs) that would serve a key regula-
tor of these two distinct processes (Schofield, 1978). The
stem cell niche, then, was envisaged to be a physiological
microenvironment consisting of specialized cells that
would physically anchor the stem cell and provide the nec-
essary factors to maintain its stemness.
Subsequent studies have shed light on the prominent
role of the niche in specifying adult stem cell fate determi-
nation. Anchoring stem cells to the niche through cell-cell
contacts is critical for physically sequestering stem cells
such that they remain both close to niche factors that
specify self-renewal and far from differentiation stimuli.
In theDrosophila adult testis and ovary, in particular, the
anatomical structure of the germline stem cell (GSC) niche
is now well-defined. In the Drosophila adult testis, for
instance, GSCs are positioned directly adjacent to a clus-
ter of postmitotic somatic cells termed the hub (Li and Xie,
2005). The hub secretes proteins that activate JAK-STAT-
and BMP-related signaling pathways critical for GSC self-
renewal and maintenance. When a male GSC divides, itgives rise to one daughter cell that remains tethered via
adherens junctions to the niche, where it receives local
signals supporting self-renewal, while the other daughter
cell is displaced away from the hub and subsequently
initiates differentiation. As in the male GSC niche, the
Drosophila ovary GSC niche is comprised of inner germa-
rial sheath cells andcap cells that contactGSCs via E-cad-
herin-mediated cell adhesion. This physical docking of
stem cells to the niche is essential for GSC maintenance.
In recent years, niches have also been identified for
mammalian stem cells in the intestinal, neural, epidermal,
and hematopoietic systems (Li and Xie, 2005). As with
Drosophila GSCs, mammalian adult stem cell niches reg-
ulate cell fate by providing cues in the forms of both cell-
cell contacts and secreted factors. Numerous signal
molecules have been implicated in niche control of cell
fate, including Hedgehog, Wnts, BMPs, fibroblast growth
factor (FGF), and Notch. In the skin epidermis, for in-
stance, hair follicle stem cells (HFSCs) responsible for
hair follicle and sebaceous gland regeneration are located
in a region called the bulge. During the process of hair
follicle morphogenesis, HFSCs in the bulge are regulated
through spatially and temporally dynamic interactions with
a specialized mesenchymal structure called the dermal
papilla. The dermal papilla is the source of important sig-
nals that regulate the HFSC activity, such as inhibitors
of the Wnt and BMP pathways (Moore and Lemischka,
2006). Similarly, the modulation of stem cell activity in
the intestine is subject to cues derived from underlying
mesenchymal cells that surround the crypt. As in the
HFSC niche, the intestinal stem cell niche is comprised
in part by mesenchymal cells, in this case pericryptal
fibroblasts, that secrete modifiers of the Wnt and BMP
signaling pathways.
Importantly, recent work has revealed that the interac-
tions between stem cells and their niches may be moreCell Stem Cell 1, December 2007 ª2007 Elsevier Inc. 607
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multiple groups have contributed to a more complete
understanding of how the balance between self-renewal
and differentiation is maintained for adult HSCs. Some re-
ports have suggested that, rather than being statically
associated with one niche, HSCs may occupy two ana-
tomically and physiologically distinct niches, an osteo-
blast niche and a vascular niche, and shuttle between
them (reviewed in Kaplan et al., 2007; Li and Xie, 2005).
Furthermore, osteoblasts lining the endosteal surface of
the bone (at the bone-hematopoietic interface) may func-
tion as the ‘‘quiescent niche,’’ whereas the endothelial
cells lining bone marrow and spleen sinusoids may
comprise the ‘‘activated niche’’ inducing HSC expansion
and differentiation. The possible promiscuity and mobili-
zation of HSCs to multiple niches suggests that niches in
general may be highly dynamic in nature, which may
have important ramifications in the search for niches in
cancer, as well.
The Cancer Stem Cell Hypothesis
It has been proposed that tumors arise from a rare popu-
lation of cells with stem cell properties, often termed can-
cer stem cells (CaSCs) (Al-Hajj et al., 2003; Lapidot et al.,
1994). According to this hypothesis, only a small fraction
of cells within certain tumors are tumorigenic—that is,
only the CaSCs can produce all of the cells necessary to
repopulate a tumor. The bulk of the tumor is comprised
of cells that are differentiated and do not harbor tumori-
genic potential. In this nascent field, some confusion has
arisen due to the semantics involved; to many, the use
of the term cancer ‘‘stem cell’’ carries the implication
that cells in the tumorigenic fraction harbor all properties
of normal stem cells. Yet, truemultipotency and asymmet-
ric division of CaSCs has yet to be rigorously demon-
strated in most solid tissues. Therefore, some investiga-
tors have advocated the use of a different term, such as
‘‘tumor-initiating cell’’ rather than cancer stem cell, to de-
scribe the subset of cells with tumorigenic potential (Hill
and Perris, 2007).
Like normal stem cells, CaSCs would be marked by
their ability both to self-renew and to differentiate to
specialized cell types with limited proliferative potential.
Both properties of CaSCs have been tested with limiting
dilution and serial transplantation experiments. Evidence
for the existence of CaSCs began in the hematopoietic
system with the 1994 demonstration that only a subset
of cells from human acute myeloid leukemia (AML)
patients were able to engraft in severe combined immuno-
deficiency disease (SCID) recipient mice (Lapidot et al.,
1994). These presumptive leukemic stem cells (LSCs)
were prospectively isolated and determined to have
a CD34+CD38 phenotype. Their frequency was rare (ap-
proximately 1 in 250,000 cells). Later studies used lineage-
tracing to show that a single LSC could give rise to the rep-
ertoire of populations of leukemia cells (Hope et al., 2004).
The isolation of CaSCs has also been reported from
various human solid tumors. The subpopulation of breast
cancer cells that were CD44+CD24/low were described608 Cell Stem Cell 1, December 2007 ª2007 Elsevier Inc.as breast CaSCs based on the ability to regenerate tumors
serially from eight out of nine patients when transplanted
into the mammary fat pads of nonobese diabetic/SCID
mice (Al-Hajj et al., 2003). While tens of thousands of the
non-CaSC fraction were unable to propagate tumors in
this system, as few as 100 of the breast CaSCs could
give rise to tumors that phenotypically resembled the orig-
inal tumor. The prospective isolation of brain CaSCs was
suggested when only CD133+ brain tumor cells were
able to propagate xenografted tumors in NOD/SCID
mice that closely resembled the original (Singh et al.,
2004). Although initiated by cells that were CD133+, the
resulting tumors contained a mixture of cells of both
CD133+ and CD133, indicating that the CaSCs may be
able to give rise to differentiated cells. In colon cancer,
CD133+ cells (approximately 2.5% of the population),
but not CD133 cells, were able to give rise to tumors
when transplanted subcutaneously into NOD/SCID mice
or in renal capsule xenografts (Ricci-Vitiani et al., 2007).
It is important to note that, while markers such as CD44
or CD133 may enrich for tumor-initiating cells in breast
or colon cancer, these molecules are not expressed
exclusively by tumor cells but also by various normal cells
in the tissue. Thus, the true cancer-initiating cells in a given
organ are only a subset of the sorted cells. Additional
markers should allow increased specificity for improved
identification and separation. Another important issue to
address will be the phenotypic stability of this tumor-
initiating subset over time. How does CaSCs gene expres-
sion change over the course of tumorigenesis or during
the shift from growth in vivo to experimentation in vitro?
A bewildering issue for stem cells, whether in normal
tissues or in cancer, is their frequency. Is the stem cell
number fixed, or is it dependent on isolation methods
and the microenvironment in which cells find themselves?
A case in point is the number of mammary stem cells. Any-
thing from 200,000 cells to as few as 50 unsorted cells
(when transplanted in Matrigel [Moraes et al., 2007]) and
even one cell from a stem cell-enriched population can re-
constitute a complete mammary ductal tree, depending
on the detailed method of transplant. This has led to wildly
diverging estimates of 1/5000–1/50 for the frequency of
mammary stem cells. Is it context and environment?
Can any cell be converted to a stem cell if the microenvi-
ronment or niche is right, or is a special phenotype re-
quired? If the same is true of tumors, then the need for
the usual inoculum of 500,000 cells in transplantation ex-
periments may represent our inability to create the niche
required for tumor take, rather than the presence of
a rare tumor-repopulating cell.
A Cancer Stem Cell Niche?
In light of the significant role of the normal stem cell niche
in controlling fate determination, it has been proposed that
a ‘‘CaSC niche’’ exists and that interactions with this
tumor niche may have a similar role in specifying a self-re-
newing population of tumor cells. Increasing evidence has
emerged that factors derived from the tumor microenvi-
ronment serve to regulate cancer cells. Genetic studies
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that stromal cells are altered in a subset of disorders
(Howe et al., 1998). Sustained expression in vivo in the
mammary gland of stromelysin-1/matrix metalloprotei-
nase-3 (MMP3), a stromal enzyme that destroys base-
ment membrane, can lead to epithelial tumorigenesis
(Sternlicht et al., 1999). In addition, damage to surround-
ing stromal cells can influence the corresponding epithe-
lial cells toward a neoplastic state. Irradiation of mammary
stroma, for instance, promotes tumorigenesis of unirradi-
ated epithelial cells (Barcellos-Hoff and Ravani, 2000).
Similarly, carcinoma-derived (but not normal) prostate
fibroblasts stimulate tumor progression in prostate epithe-
lial cells (Olumi et al., 1999).
Similarities between the normal stem cell niche and the
tumor microenvironment continue to be uncovered. In
basal cell carcinoma of the skin and in diverse other solid
tumors, fibroblasts that comprise the tumor cell niche are,
indeed, molecularly distinct from those that comprise the
normal stroma (Sneddon et al., 2006). In a striking parallel
to normal stem cell biology, cells that comprise the tumor
niche produce some of the same molecular factors (e.g.,
BMP antagonists) that are produced by the normal stem
cell niche tomaintain the stem cell pool. Genomic profiling
revealed that, unlike their normal counterparts, tumor-
associated dermal fibroblasts express high levels of the
secreted BMP antagonist GREMLIN 1. In contrast, the
basal cell carcinoma cells themselves express BMP2
and BMP4. Gremlin 1 protein supports the basal cell car-
cinoma cells in a less differentiated, more expansive state
ex vivo, suggesting that expression of secreted BMP
antagonists by tumor-associated stromal cells may pro-
mote self-renewal of tumor cells in vivo.
While evidence for an instructive role of the tumor mi-
croenvironment has been promulgated for years, how-
ever, evidence for an anatomically and/or physiologically
specialized environment that constitutes a true CaSC
niche is still in its infancy. Nevertheless, data have begun
to emerge that support the idea of a veritable CaSC niche.
Recently, for instance, brain cancer stem cells were visu-
alized to live in a vascular niche that secretes factors that
promote their long-term growth and self-renewal (Calabr-
ese et al., 2007). Increasing the number of endothelial cells
in brain tumor xenografts expands the proportion of self-
renewing cells in the tumor and also hastens tumor initia-
tion and growth. Disrupting this niche impairs brain cancer
stem cell self-renewal, thereby significantly inhibiting
tumor growth—providing some support for the theory
that targeting the unique aberrant microenvironment of
CaSCs may be a critical aspect of effective cancer ther-
apy. As a cautionary note, however, evidence from
HIF-1a-deficient astrocytomas has suggested that when
brain tumors are unable to induce angiogenesis, they
successfully adapt to this disadvantage by migrating along
existing normal blood vessels to propagate (Blouw et al.,
2003).
Work in the hematopoietic system suggests a possible
role for the niche in regulating CaSC maintenance. Spe-
cialized microenvironments of bone marrow endothelialcells appear to be required for the homing and engraft-
ment of both normal HSCs and leukemic cells (Sipkins
et al., 2005). Moreover, both extracellular matrix (ECM)
components and signalingmolecules in the HSCmicroen-
vironment can promote cell survival in AML, providing
resistance to chemotherapeutic treatments (De Toni
et al., 2006). An important unresolved question about
CaSC niches, if they exist, is whether there are the equiv-
alents of both the quiescent and active niches, as is the
case for normal HSCs. If so, then it may be the relative
time spent in one versus the other, or alternatively the
availability of the quiescent versus activated niches, that
distinguishes cancer from the normal case. Interestingly,
loss of the quiescent niche for normal HSC results in my-
eloproliferative disease. The possibility of multiple CaSC
niches should be kept in mind for future studies. Indeed,
if there are distinct CaSC niches that specify dormancy
versus expansion, the molecular cues that distinguish
the two will be critical to our understanding of how to ther-
apeutically target CaSCs. If cues from the microenviron-
ment do indeed regulate CaSC activity, this information
will be crucial in deciphering results from experimentation
of CaSCs in vitro. For instance, if stemness is a function of
microenvironment, then the properties of CaSCsmay vary
significantly depending on the in vitro context in which we
interrogate them; this would have important implications
for establishing appropriate ex vivo model systems for
studying CaSCs.
There are several possiblemodels for CaSC-niche inter-
actions (Figure 1). The CaSC may not require a distinct
niche for expansion andmay instead be capable of surviv-
ing in the normal stem cell niche (Figure 1A). Alternatively,
a distinct CaSC niche may be necessary for activation.
CaSCsmay be dependent on the pre-existence of a favor-
able niche for expansion (Figure 1B). Just as with normal
stem cells, the niche may be important for maintaining
asymmetric division of CaSCs and for tethering CaSCs
close to signals that maintain stem-like properties. In-
stead, CaSCs may be capable of providing signals that
instruct an otherwise quiescent niche to become acti-
vated, effectively hijacking the niche (Figure 1C). Signals
from the CaSCs could result in amplification of an acti-
vated niche that already exists (possibly at low frequency),
permitting further expansion of the tumor (Figure 1D).
Alternatively, CaSCs may be niche independent (Fig-
ure 1E). That is, they may have acquired the ability to pro-
vide themselves with the necessary factors for expansion
and self-renewal—processes that would otherwise nor-
mally be restricted by the niche. Lastly, theremay be a dis-
crete niche that is inhibitory for CaSCs, providing factors
that induce differentiation or death (Figure 1F).
The Metastatic Niche
For metastatic spread to occur, tumor cells must reduce
cell-cell contacts and gain migration to distant sites. Ac-
cordingly, a number of the same signals appear to underlie
activation and mobilization of normal HSC as well as can-
cer cell invasion and metastasis (Kaplan et al., 2005). For
instance, chemokines and their receptors are importantCell Stem Cell 1, December 2007 ª2007 Elsevier Inc. 609
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a role in specifying the metastatic destination of breast
tumor cells. The chemokine receptors CXCR4 and CCR7
are expressed at high levels in malignant breast tumors
and in metastatic lesions, and their cognate ligands
CXCL12/SDF-1a and CCL21 are expressed in organs
that are the first sites of breast cancer metastasis. In the
bone marrow, MMP9 is important for the recruitment of
and mobilization of hematopoietic stem and progenitor
cells from the quiescent bonemarrow niche to the prolifer-
ative niche. Similarly, in tumors, there is mounting evi-
dence that various MMPs play roles in tumor invasion
Figure 1. Models for the Relationship between Cancer Stem
Cells and Their Niches
An activated niche providing necessary factors (shown as red circles)
for expansion and self-renewal is depicted in blue,whereas aquiescent
niche lacking such factors is depicted in green.
(A) Normal and CaSC nichesmay be one and the same. CaSCsmay be
activated in response to cues from the normal stem cell niche.
(B) An activated niche may precede the advent of the CaSC. CaSCs
may be dependent on the pre-existence of a favorable niche for expan-
sion.
(C) CaSCs may provide signals (purple arrow) that instruct an other-
wise quiescent niche to become activated.
(D) Signals from the CaSCs (blue arrow) may result in amplification of
the activated niche, permitting further expansion of the tumor.
(E) CaSCs may be niche independent. That is, they may acquire the
ability to cell-autonomously provide the necessary factors for expan-
sion and self-renewal that are normally restricted by the niche.
(F) An inhibitory niche, shown in purple, may exist as distinct from the
normal or CaSC-activating niches. In this case, signals from the niche
shut down the CaSCs, inducing differentiation or death.610 Cell Stem Cell 1, December 2007 ª2007 Elsevier Inc.and metastasis. MMP9 is induced in clusters of premeta-
static lung endothelial cells through VEGF Receptor 1
(VEGFR1) signaling from distant primary tumors (reviewed
in Kaplan et al., 2007).
As noted earlier, adhesion molecules are necessary for
anchorage of stem cells to the niche; they also mediate
homing of circulating hematopoietic progenitor cells. The li-
gands fibronectin and VCAMare expressed on newly form-
ing blood vessels and are recognized via integrin a4b1 ex-
pressed onprogenitor cells (Jin et al., 2006). Thus, adhesion
molecules facilitate homing of normal hematopoietic pro-
genitor cells to neovasculature. In addition, however, they
are involved in processes that are necessary for invasion
of metastatic tumor cells, such as loss of cell-cell adhesion
and gain of cell motility (Christofori, 2006). Similarly, integ-
rins are required for migration of normal HSCs and have
also been associated with migration of tumor cells.
The ability of a tumor tometastasizemay depend first on
the tumor cells (possibly the CaSCs) acquiring the propen-
sity of stem cells to wander from niche to niche and sec-
ond on the ability of the cancer cells to establish distant
niches that are hospitable for local occupancy. The con-
cept of a ‘‘premetastatic niche’’ is supported bywork dem-
onstrating that VEGFR1-expressing bone marrow-derived
hematopoietic progenitor cells are directed to sites of
futuremetastasis by factors secreted by the primary tumor
cells (Kaplan et al., 2005). Thus, in response to signals from
the tumor cells, bonemarrow-derived cells (BMDCs) colo-
nize the premetastatic niche before metastatic tumor cells
have arrived. Interestingly, these niches, like normal
niches, are marked by ECM components such as fibro-
nectin. When niche components are disturbed (by treating
with blocking antibodies against VEGFR1, for instance, or
by depleting VEGFR1+ cells from the bonemarrow), tumor
metastasis can be prevented, pointing to potential func-
tional significance of the niche in creating a permissive
environment for successful dissemination. Together with
the phenomenon of tissue tropisms during metastasis,
these lines of evidence point to a possible role for cancer
cell-niche interactions in guiding metastasis.
Therapeutic Implications and Future Work
The feasibility of targeting the CaSC niche therapeutically
will depend, in part, on the degree of similarity between
the normal and CaSC niches. If the factors that promote
survival and proliferation are redundant in both contexts,
then targeting niche-derived signals could also affect
normal stem cell pools. As key distinguishing features
are identified, however, therapies aimed at leveraging
the differences between the normal and CaSC niches
will be vital for therapeutic purposes. The successful
depletion of leukemia-initiating cells, but not normal
HSCs, in a mouse model of myeloproliferative disease
has provided some support for the notion that selective
targeting of CaSCs may be possible (Yilmaz et al., 2006).
Toward this end, an important step in the CaSC field will
be the ongoing identification of additional markers that
provide even more specific isolation and characterization
of CaSCs, particularly in solid tissues. Of particular utility
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localization and visualization of CaSCs in situ, as this is
bound to facilitate anatomical localization of the niche as
well. Ideally, markers that allow for sorting niche cells
will also be developed, although this will likely be a signif-
icant task given the complexity of the niche—comprising
fibroblastic cells, myeloid and other inflammatory cells,
endothelial and perivascular cells (or their progenitors),
and ECM components.
As CaSCs continue to be better characterized and the
components of their niche identified, functional studies
will be crucial for understanding the contribution of de-
fined molecular constituents to CaSC physiology. In vivo
models and ex vivo systems should prove useful in sys-
tematically characterizing the intricate molecular lan-
guage of cell-cell communication in the cancer niche.
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